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INTRODUCTION & BACKGROUND
Abstract: The underlying problem for two of
the three most common patterns of
unexpected hospital deaths (PUHD) is
hypoventilation1. Current methods of postoperative respiratory monitoring give
delayed signals and have a high false
positive rate leading nurses to ignore
alarms. We hypothesize a combination of
low cost sensors can be capable of
differentially identifying obstructive sleep
apnea and ventilatory depression in realtime. Such a monitor would be useful during
space travel when monitoring personnel are
limited following an injury or if astronauts
were to be sedated during extended travel.
Methods:
Twenty-six
subjects
were
recruited to participate in a study of the
effects of Propofol and Remifentanil.
Throughout the day, these patients were
exposed to varying levels of both drugs
simultaneously
via
target
controlled
infusions. These patients were attached to a
multitude of breathing and oxygen monitors.
Adverse respiratory events were identified
and recorded by clinicians. We developed
breath detection algorithms and used these
to identify respiratory problems in our
signals which were compared against
clinician input. Results: When comparing
our sensors versus clinician opinions,
multiple
combinations
of
sensors
successfully differentially identify adverse
respiratory events. Conclusion: Using only a
combination of low cost sensors, we can
provide real time respiratory event data to
nurses and practitioners.

The underlying problem for two of the three
most common patterns of unexpected
hospital deaths (PUHD) is hypoventilation1.
Type II PUHD (CO2 narcosis) involves a
reduction in respiratory rate and/or tidal
volume, and if supplemental oxygen is
being provided, a pulse oximeter will not
detect the problem until the hypercarbia is
significantly advanced and the patient is
near respiratory arrest. Type III PUHD is
induced by obstructive sleep apnea in the
presence of arousal failure, and is
recognized as a repetitive sequence of
cyclic apneas and self-arousals which
precede the final apnea. A pulse oximeter
alarms with each apneic period and will
likely be interpreted as generating many
false positive alarms.1 The risk of opioidinduced
respiratory
depression
in
postoperative patients is greatest in the first
24 hours after initiation of opioids2, and
opioids are the most commonly used drug
for treating pain in the postoperative
period.3
These problems would be especially
apparent in space travel where monitoring
personnel are limited due to either sedation
of crew members or an injury rendering the
crew short-handed.
Respiratory depression is caused by druginduced inhibition of the breathing control
center of the brain stem. Partial to full
airway obstruction is an anatomic problem
involving the soft palate, tongue base,
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and/or epiglottis, caused by drug-induced
decreases in airway patency and muscle
tone. Sedatives and opioids depress the
response to elevated CO2 (reduced drive to
breathe), worsen arousal, cause airway
obstruction, and change sleep patterns4-8
In the postoperative period, most adverse
respiratory events occur during the first 24
hours of opioid administration.2 During this
period,
pulse
oximeter
monitoring,
supplemental oxygen, incentive spirometry,
and intermittent nursing observation are the
primary interventions used to fend off
adverse respiratory events. For inpatient
monitoring, pulse oximetry is often
inadequate. On a busy hospital floor, it is
difficult to respond to multiple remote
advisory pulse oximetry alarms. Pulse
oximeter alarms are ignored because they
have a high false-positive alarm rate due to
movement artifact and displacement.9,10
Pulse
oximetry
primarily
monitors
oxygenation instead of ventilation; the SpO2
signal is a delayed indicator for apnea or
hypopnea, particularly when supplemental
oxygen is given. By the time the pulse
oximeter alarms, an apneic patient is
already in danger of hypoxia, brain injury
and death.
Existing
technologies
may
improve
monitoring of adverse respiratory events in
this setting, but are either costly or difficult
to implement. For example, monitoring
ventilation with capnography is expensive
and it can be problematic to sample the
exhaled gas with a face mask or nasal
cannula
in
non-intubated
patients.11
Acoustic respiratory rate monitoring may be
able to detect airway obstruction, but it is
costly and may not have sufficient sensitivity
to reliably detect apnea events.12 We
suggest that there is an urgent need for a
low cost, reliable respiratory depression
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monitoring technique that can be integrated
with the signals from the pulse oximeter to
give additional physiologic information about
a patient’s sufficiency of both ventilation and
oxygenation.
Currently, we are exploring the value of
integrating the information from a set of lowcost physiologic monitors that can be
adapted to monitoring patients in a hospital
floor setting. In addition to the red and
infrared component signals that comprise
the pulse oximeter plethysmography
waveform,
we
intend
to
integrate
information from motion sensors on the
finger, head, abdomen, chest wall and bed,
temperature, pressure and carbon dioxide
sensors embedded in a nasal cannula and
acoustic respiratory rate via a microphone
on the throat. We will determine from the
tested set the fewest number and least
costly types of sensors that can be used to
accurately identify and quantify ventilatory
depression and airway obstruction, provide
reliable measures of oxygenation AND
ventilation, provide specific alarms, and
avoid artifact. A monitor which correctly
identifies all the different types of respiratory
events individually would allow nurses and
clinicians to better their care to help patients
in need.
Our team previously characterized various
effects of sedatives combined with opioids
using drug interaction models. Specifically,
we characterized the interaction of Propofol
and Remifentanil on metrics of airway
obstruction and intolerable ventilatory
depression in volunteers.8 We defined
intolerable ventilatory depression as a
respiratory rate less than 5 breaths per
minute and airway compromise as either
partial (tidal volume less than 3 mL/kg in the
presence of a respiratory effort) or complete
obstruction. Respiratory compromise was
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defined as either intolerable ventilatory
depression or airway obstruction or both.
Using this model, predictions of respiratory
compromise (0 to 100%) can be made for
various dosing schemes of Propofol and
remifentanil.8 (Figure 1). In general, dosing
schemes that led to high concentration of
Propofol were more likely to produce airway
obstruction
and
higher
doses
of
Remifentanil were more likely to produce
intolerable ventilatory depression.
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Figure 1: A: Dose of a drug, first as a bolus,
then as a continuous infusion. B: effect site
concentration (Ce) Corresponding to the
given dose and C: Observed effect
(sedation) for a single administered drug.
Time points 1-5 correspond to a likelihood of
effect in D: Effect and corresponding drug
concentrations
resulting
in
stated
probabilities for respiratory
METHODScompromise.

A 20 gauge venous catheter was placed in
an antecubital vein under local anesthesia
(0.2 mL of 0.5% lidocaine) for the purpose
of hydration and drug administration. The
IV site was similar in all subjects. A
maintenance infusion of 0.9% sodium
chloride was administered at 1 ml/kg/hour
throughout the study. Continuous infusions
of Remifentanil and Propofol was infused
into this peripheral IV.
Subjects were instrumented with a
noninvasive blood pressure cuff, ECG
leads, pulse oximeter(s), motion sensors,
respiratory inductance plethysmography
"chest bands", capnography nasal cannula,
nasal gas pressure sensor, nasal thermistor
and an acoustic respiratory rate sensor.
These or similar monitors were placed to
measure respiratory rate, tidal volume, endtidal CO2, SpO2, blood pressure, body
motion and heart rate. Chest and abdominal
wall excursion were measured with the
attached motion sensors and the respiratory
inductance
plethysmography
bands.
Changes in respiration pattern were
displayed as real-time changes in CO2
waveforms. A processed EEG monitor
and/or a cerebral oximeter were optionally
placed to record data for later analysis. A
motion sensor was also placed on the bed.
These devices were operational during the
entire study day. Data from devices was
electronically captured and recorded for
later analysis. Continuous variables such as
motion
waveforms,
pulse
oximetry
waveform, capnogram, and nasal airway
pressure were digitized during data
collection periods at 50-1000Hz during data
collection periods at each target effect site
concentration pair. Discrete variables were
recorded every 5 seconds or as soon as
data were available during data collection
periods. Examples of discrete variables
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include heart rate, SpO2, PetCO2, systolic
blood pressure, diastolic blood pressure and
respiratory rate. The tidal volume was
occasionally measured with a differential
pressure flow sensor attached to an
anesthesia mask or mouthpiece in order to
calibrate
the
respiratory
inductance
plethysmography bands.

subject, the steady state drug dose was
maintained for a period of data collection.

Each subject received Propofol and
Remifentanil. Similar to previously collected
data from our volunteer laboratory (Kern et
al, 2004), each drug was administered using
a
computer
controlled
(Stanpump14)
continuous infusion pump (Pump 22;
Harvard Apparatus, Limited, Holliston, MA)
to achieve selected target effect site
concentrations.
The
effect
site
concentration
refers
to
the
drug
concentration at the pharmacologic site of
action. Pharmacokinetic
parameters
published by Minto et al.15 and Schnider et
al.16 was used for Remifentanil and
Propofol respectively.

Breath detection for the capnogram was
performed using the algorithm built in to the
capnometer (LoFlo, Philips, Wallingford
CT). Breath detection algorithms for the
respiratory inductance plethysmography
bands, nasal pressure, and thermistor was
performed using an algorithm that
measured signal excursion the baseline.
Samples of these signals are shown in
figure 2.

We administered Propofol and Remifentanil
pairs in a dose escalation scheme with
small steps in order to creep up to the
desired target effects of respiratory
depression, airway obstruction and both
effects while avoiding overshoot. To
accomplish this, the Propofol was dosed in
a range of 0.75 - 4 mcg/mL in dose
escalation steps of approximately 0.5
mcg/mL. Remifentanil was dosed in a range
of 0.75 to 4.0 ng/mL in escalation steps of
approximately 0.25-0.5 ng/mL. If overshoot
was observed for a given target effect site
concentration pair, the target effect site
concentrations
were
lowered
so
assessments could be made during the
target effects of respiratory depression or
airway obstruction or both. Once the drug
concentration pair was identified which
resulted in the target effects for a given

From the data collected, we isolated all the
ten minute periods during which there was
no interaction with the patient. This provided
us with 1128 minutes (18.8 hours) of
continuous monitoring to be analyzed.

We then created definitions based on our
study protocols to identify respiratory
problems. If no breaths were detected
during the last 30 seconds of monitoring by
either signal, a central apnea flag was
created in the data. This implies that one
signal in a pair may identify a breath during
a given 30 second interval and still identify a
central apnea. In order to identify complete
obstructions, we relied on pairing signals
above and below the point of obstruction
(the trachea). To this end, we grouped the
chest
bands,
accelerometers,
and
impedance signals together as ‘body’
signals and we grouped the nasal pressure,
thermistor, and capnometer signals together
as ‘head’ signals. Whenever a breath was
identified in the ‘body’ signal, the algorithm
would search for a ‘matching’ breath in the
‘head’ signal. The width of the search region
for matching breaths was dependent on the
signals included. For example, the
capnogram is the most ‘delayed’ signal in
terms of identifying breaths. This is due to
the side stream technology that takes time
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Figure 2: Sample waveforms from some of the signals applied during our study. In order
of top to bottom, these are respiratory inductance plethysmography bands, capnography,
nasal pressure sensor, chest impedance, and nasal-oral thermistor. Red x’s denote
breaths identified through our algorithms except in the case of impedance which is
recorded directly as a breath rate from the equipment.
to sample air from the circuit and the
underlying breath detection mode that
identifies the end of expiration. If no
matching breath was found in the ‘head’
signal, then the breath was marked as
‘obstructed’. Any period of two or more
obstructed breaths in a row was marked as
an obstructive apnea. A simple summary of
these definitions are presented in figure 3.
To begin our analysis, we isolated
respiratory events that were confirmed by

the clinicians. These periods were
specifically identified as containing either
central or obstructive apnea. Thirty nine
obstructive apnea events and thirty central
apnea events were identified in this manner.
We also identified thirty periods of ‘normal’
breathing (when the drug level was low), to
use as a negative control. To analyze
hypopnea, we relied solely on the hypopnea
flags created by the Phillips capnogram in
leiu of clinician input because the clinicians
were relying on the capnogram to identify
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Figure 3: Method for combining head and body signals in a way that differentially identifies
central and obstructive apnea. When there are no breaths in either signal, central apnea is
marked. If there are breaths in the body waveform and no breaths in the head waveform,
obstructive apnea is marked.
hypopneas. That is, whenever the
capnogram identified 5 or fewer breaths in
the past 60 seconds, a hypopnea flag was
created. Thus there were significantly more
hypopnea
events
included
in
our
comparison.
With these definitions in place, alarm flags
were created for each signal and pair of
signals. If more than fifty percent of the
period denoted by the clinician was
matched by the signal alarm algorithm, then
the period was denoted a ‘true positive’. If
any alarm was created during our negative
control periods, no matter the length, then
the period was denoted as a ‘false positive’.
False negatives occurred if there was less
than fifty percent overlap between our
signal-based alarm and the clinician
judgement. True negatives occurred when
no alarm was created during our negative
control periods. Sensitivity and specificity
was calculated based on this data
RESULTS
Thus far, we have applied these methods to
combinations of the signals displayed in
figure 5. The results are displayed in table
1. The best signals for detecting central
apnea were the respiratory inductance
plethysmography bands, the capnometer,
and the nasal pressure sensors (and any
combination of these). The best signal

combination for identifying obstructive
apneas
was
respiratory
inductance
plethysmography in combination with a
nasal pressure sensor. For detecting
hypopnea, the most effective individual
signal was the nasal pressure sensor. The
most effective pair was nasal pressure and
respiratory inductance plethysmography
bands.
CONCLUSION
A low cost, accurate, and minimally sized
respiratory monitor would be useful during
space travel when personnel are limited
following an injury/emergency procedure or
if astronauts were to be sedated during
extended voyages.
Preliminary analysis of the signals has been
successful in proving that low cost signals
can match clinician opinion with sufficient
accuracy.
While this knowledge gives hope for moving
forward, there is still much work to be done
in creating an affordable respiratory monitor.
We plan to add even more signals to our
analysis in the future. Having a wider array
of tested signals will better allow us to
compare and contrast the strengths and
weaknesses of each. We also plan to
expand the capability of our monitors to
detect partial airway obstructions which
have thus far been left out. We also hope to
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Table 1: Results of combining different signals and comparing their output to clinician opinion
(in the case of central and obstructive apnea) or capnography (in the case of hypopnea).

Signal 2

Central
Apnea
Sensitivity

Central
Apnea
Specificity

Obstructiv
e Apnea
Sensitivity

Obstructiv
e Apnea
Specificity

N/A

1

1

N/A

N/A

N/A

.53

.8

N/A

N/A

N/A

1

1

N/A

N/A

N/A

1

1

N/A

N/A

Thermistor

N/A

.7

.96

N/A

N/A

Chest (RIP)
Bands
Chest (RIP)
Bands
Chest (RIP)
Bands
Impedance
Sensor
Impedance
Sensor
Impedance
Sensor

Capnomete
r
Nasal
Pressure

1

1

.82

1

1

1

.89

1

1

.97

.53

1

.97

.8

.09

1

.97

.8

.13

1

.8

.8

.02

1

Signal 1
Chest (RIP)
Bands
Impedance
Sensor
Capnomete
r
Nasal
Pressure

Thermistor
Capnomete
r
Nasal
Pressure
Thermistor

identify patterns in single signals that will
allow us to identify airway obstructions with
sufficient accuracy. The ability to identify
airway obstructions using only one signal
would reduce both the cost of the device
and the clutter on the patient.
Overall, we are confident these goals will be
reached and provide invaluable insight that
will allow us to save patient lives.
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Hypopnea
Sensitivity

Hypopnea
Specificity

.83

.88

.60

.81

N/A

N/A

.88

.88

.78

.87

N/A

N/A

.97

.83

.91

.80

N/A

N/A

.91

.76

.88

.67
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